Table 1.
Baseline characteristics of patients.
| ADHF (N = 96) | Control (N = 96) | P | |
|---|---|---|---|
| Male, n (%) | 54 (56.5%) | 53 (55.2%) | 0.500 |
| Age (years) | 71.53 ± 14.24 | 70.69 ± 12.57 | 0.668 |
| Hypertension, n (%) | 59 (61.6%) | 54 (56.3%) | 0.279 |
| Diabetes, n (%) | 23 (23.9%) | 11 (11.5%) | 0.018 |
| Mortality, n (%) | 39 (40.6%) | 0 (0) | 0.000 |
| Smoking, n (%) | 39 (40.6%) | 31 (32.3%) | 0.147 |
| NT-proBNP (pg/mL) Δ | 5,543 | 93.80 | 0.000 |
| (2,889.75, 10,667.25) | (27.25,187.50) | ||
| sST2 (ng/mL) Δ | 21.21 (12.89,41.26) | 8.49 (4.79, 13.81) | 0.000 |
| β1-AA OD | 0.321 ± 0.06 | 0.229 ± 0.04 | 0.000 |
| LVEF% | 46.15 ± 10.43 | 65.53 ± 6.11 | 0.000 |
| LVEDd (mm) | 53.85 ± 10.49 | 46.02 ± 4.83 | 0.000 |
| TC (mmol/L) | 4.11 ± 1.14 | 4.58 ± 0.98 | 0.000 |
| TG (mmol/L) | 1.16 ± 0.53 | 1.7 ± 0.62 | 0.000 |
| LDL-c (mmol/L) | 2.53 ± 0.97 | 2.55 ± 0.74 | 0.872 |
| PCT (ng/mL) Δ | 0.064 (0.035, 0.133) | 0.035 (0.022,0.049) | 0.000 |
| SCr (umol/L) Δ | 107.00 (83.25, 125.75) | 74.00 (62.00,90.25) | 0.000 |
| CRP (mg/L) Δ | 10.80 (2.84, 20.30) | 1.50 (0.70,3.50) | 0.000 |
Data are presented as the x± SD, the median (Δ); sST2, soluble suppression of tumorigenicity-2; β1-AA, β1-adrenoceptor autoantibody; TC, Total cholesterol; TG, triglycerides; LDL-c, low-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction; LVEDd, left ventricular end-diastolic diameter; NT-proBNP, N-terminal proB-type natriuretic peptide; PCT, procalcitonin; and SCr, serum creatinine.
P values are comparison between ADHF and Control groups.